Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasin...
用于治疗子宫内膜异位症并伴有中度至重度疼痛。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.